25-28 June 2014

Barcelona, Spain

App

Scientific Agenda

Wednesday, 25 June, 2014

12:30

Expert discussion (by invitation only): Metastatic colorectal cancer
Scientific committee and selected experts

Session I: Report from the ISCAP International Conference on GI Cancer Prevention

Chairs: Mario Dicato, MD, Eric Van Cutsem, MD, PhD and Josep Tabernero, MD, PhD

15:00

Welcome and introduction: Congress Chairs
Mario Dicato, MD, Eric Van Cutsem, MD, PhD and Josep Tabernero, MD, PhD

15:05

Keynote Lecture 1: Prevention of colorectal cancer: State of the science and treatment recommendations
Powel H. Brown, MD, PhD

Session II: Cancer of the pancreas and bile ducts

Chairs: Alfredo Carrato, MD, PhD and Malcolm J. Moore, MD

15:25

Familial pancreatic cancer
Margaret Tempero, MD

15:45

Intraductal papillary mucinous neoplasm
Pascal Hammel, MD, PhD

16:00

Surgical resection for pancreatic cancer: Anything new on the horizon?
Markus Büechler, MD

16:20

Presentation of selected abstracts
Phase 2 double-blind, placebo –Controlled trial of dasatinib added to gemcitabine for subjects with locally-advanced pancreatic cancer (LAPC)
J. Evans, et al., O-0001

Prognosis model for overall survival in locally advanced pancreatic cancer (LAPC):
An ancillary study of the LAP 07 trial
D. Vernery, et al., O-0002

16:35

Discussant
Stefano Cascinu, MD

16:45

Strategies to improve the outcome in locally advanced pancreatic cancer
Christophe Louvet, MD, PhD

17:00

Presentation of selected abstracts
NAPOLI-1: Randomized phase 3 study of MM-398 (nal-IRI), with or without 5-
fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic
pancreatic cancer progressed on or following gemcitabine-based therapy
A. Wang-Gillam, et al., O-0003

Results from a phase 2 study of ruxolitinib or placebo with capecitabine as second-line therapy in patients with metastatic pancreatic cancer: the RECAP trial
H. Hurwitz, et al. 0-0026

SPARC analysis in the phase III MPACT trial of nab-paclitaxel (nab-P) plus
gemcitabine (Gem) vs Gem alone for patients with metastatic pancreatic cancer (PC)
M. Hidalgo, et al., O-0004

17:30

Discussant: Impact of new biomarkers from MPACT
Jordan B. Berlin, MD

17:45

What is the optimal treatment for patients with metastatic pancreatic cancer?
Eileen M. O'Reilly, MD

18:05

Clinical case discussion
Guy Berchem, MD

18:20

New agents on the horizon in pancreatic cancer
Malcolm J. Moore, MD

18:35

Personalized medicine: The future in pancreatic cancer
Manuel Hidalgo, MD, PhD

18:50

Adjourn

19:00

ESO Cancer Observatory and EXCEMED Symposia begin

20:30

ESO Cancer Observatory and EXCEMED Symposia adjourn

20:30

Welcome Reception

Thursday, 26 June 2014

CLOSED SESSION (by invitation only): Intergroup Meeting - Collaboration on clinical trials

9:00

Strategy of national and international clinical trial groups

10:00

Session adjourns

Session III: Meet the expert concurrent presentations

8:00

Anal cancer
Robert Glynne-Jones, FRCR, FRCP and Karin Haustermans, MD, PhD
Cholangiocarcinoma and gall bladder cancer
Thomas Gruenberger, MD and Juan W. Valle, MD
Thrombosis in GI cancer (including novel anticoagulants)
Mario Dicato, MD
Recent advances in the management of GIST
John R. Zalcberg, MD, PhD, MBBS
Challenges and limitations in rectal cancer management
Chris Cunningham, MD, FRCSEd and Andre D’Hoore, MD, PhD
Implementing RAS testing in clinical practice: How to test, what to test and when. Quality control of testing
Han Van Krieken, MD and Jean-Yves Douillard, MD, PhD

8:50

Session adjourns

Session IV: Esophageal cancer

Chairs: Philippe Rougier, MD, PhD and Andrés Cervantes, MD, PhD

9:10

Treatment of Barrett’s esophagus: Update on new endoscopic modalities
Jacques J. Bergman, MD, PhD

9:20

Presentation of selected abstract
RTOG 0436: A phase III trial of cisplatin, paclitaxel and radiation with or without cetuximab in the nonoperative treatment of esophageal cancer
D. Ilson, et al., O-0005

9:30

Which neoadjuvant treatment in GEJ?
Marc Ychou, MD, PhD

Pro chemotherapy
Christopher G. Willett, MD

10:00

Surgery for esophageal cancer: How can we improve?
Christophe Mariette, MD, PhD

10:15

Discussion and cases
Andrés Cervantes, MD, PhD

10:30

Break and poster viewing
Abstracts to be presented: Clinical/basic non-CRC abstracts

Session V: Rare tumors: Neuroendocrine tumors and gastrointestinal stromal tumors

Chairs: Michel Ducreux, MD, PhD and Ramon Salazar Soler, MD

11:00

Relevance of molecular markers for management of GIST tumors
John R. Zalcberg, MD, PhD, MBBS

11:20

Recommendations for the management of pancreatic NET
Bertram Wiedenmann, MD

11:40

Recommendations for the management of small bowel NET
Marianne Pavel, MD

12:00

Liver directed therapy for liver metastases of NET
Philippe Ruszniewski, MD

12:20

Efficacy and toxicity of peptide receptor targeted radiopeptide therapy
Dik J.Kwekkeboom, MD, PhD

12:40

Round table discussion

12:50

Travel Grant Award Ceremony

12:55

Session adjourns

13:10

Concurrent luncheon symposia begin

14:40

Concurrent luncheon symposia adjourn

Session VI: Cancer of the liver

Chairs: Richard M. Goldberg, MD and Roberto Labianca, MD

14:55

Pathologic and molecular changes in HCC
Josep M. Llovet, MD

15:15

How to decide on the optimal treatment algorithm for HCC?
Chris Verslype, MD, PhD

15:35

New molecular targeted agents in HCC
Andrew X. Zhu, MD, PhD, FACP

15:55

Keynote lecture 2:Endpoints and Novel Design for GI Cancers in the Era of Targeted Therapies
Daniel J. Sargent, PhD

16:30

Break and poster viewing
Abstracts to be presented: Clinical/basic non-CRC abstracts

Session VII: Gastric cancer

Chairs: David H. Ilson, MD, PhD and Jin Li, MD, PhD

17:00

Hereditary diffuse gastric cancer and genetic syndromes of stomach cancer: What clinicians need to know
Fátima Carneiro, MD, PhD

17:20

Challenges in the surgical management of gastric cancer
William H. Allum, MD, FRCS

17:40

Should all patients be treated with adjuvant and/or neoadjuvant treatment?
David Cunningham, MD

18:00

Presentation of selected abstract
RAINBOW: A global, phase 3, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of gastric cancer following disease progression: Western population subgroup
E. Van Cutsem, et al., O-0006

18:10

What is the reference cytotoxic regimen in advanced gastric cancer?
Florian Lordick, MD, PhD

18:25

Case presentation and discussion
David H. Ilson, MD, PhD

18:35

Is gastric cancer different in Asian and Western
Jin Li, MD, PhD

18:50

New targeted agents in gastric cancer
Manish A. Shah, MD

19:10

Session adjourns

Friday, 27 June 2014

Session VIII: Meet the expert concurrent presentations

Parallel with Session IX – Presentation of selected abstracts IIA, Session X – Presentation of selected abstracts IIB and Session XI: ESMO session: Focus on young medical oncologist

8:00

Peritoneal metastases: Challenges for the surgeon
Andre D’Hoore, MD, PhD and Dominique Elias, MD, PhD
Carcinoma of unknown origin
Nicholas A. Pavlidis, MD, PhD, FRCP
Treatment of elderly patients with GI cancer
Demetris Papamichael, MB, BS
Workshop: What are resectable liver metastases?
René Adam, PhD; Richard M. Goldberg, MD;and Thomas Grüenberger, MD

8:50

Session adjourns

Session IX – Presentation of selected abstracts IIA

Parallel with Session VIII: Meet the expert concurrent presentations, Session X- Presentation of selected abstracts IIB and Session XI: ESMO session: Focus on young medical oncologist

Chairs: Alfredo Carrato, MD, PhD and Josep Tabernero, MD, PhD

8:00

Presentation of selected abstracts
Prognostic value of KRAS mutations in stage III colon cancer: Post-hoc analyses of PETACC8 Phase III trial
J. Taieb, et al., O-0024

Subgroup analyses in RAS mutant, BRAF mutant and “all wt” metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study
C. Cremolini, et al., O-0007

Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone, as second-line treatment for patients with KRAS wild-type metastatic colorectal cancer: the POSEIDON phase I/randomized phase II trial
E. Elez, et al., O-0008

Phase I study of the investigational anti-guanylyl cyclase C (GCC) antibody-drug conjugate (ADC) MLN0264 in adult patients with advanced gastrointestinal malignancies expressing GCC
J. Faris, et al., O-0009

AXE beam: Neo-adjuvant triplet versus doublet therapy with radiation and total mesorectal excision for locally advanced rectal cancer – A randomized phase II study at the end of recruitment
G. Chiritescu, et al., O-0010

Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from metastatic colorectal cancer patients treated with panitumumab or cetuximab monotherapy
M. Peeters, et al., O-0011

2nd-line therapies after 1st-line therapy with FOLFIRI in combination with cetuximab or bevacizumab in patients with KRAS wild-type metastatic colorectal cancer (mCRC)-analysis of the AIO KRK 0306 (FIRE 3)- trial
D. Modest, et al., O-0018

9:10

Discussant
Alfredo Carrato, MD, PhD

9:25

Session adjourns

Session X – Presentation of selected abstracts IIB

Parallel with Session VIII: Meet the expert concurrent presentations, Session IX- Presentation of selected abstracts IIA and Session XI: ESMO session: Focus on young medical oncologist

Chairs: Bernard Nordlinger, MD and Thomas Seufferlein, MD

8:00

Presentation of selected abstracts
Are the benefits of aspirin in colorectal cancer limited to PIK3CA mutated cancers?
R. Langley, et al., O-0012

Dietary fatty acids intake and colorectal cancer risk: The Rotterdam study
B. Kraja, et al., O-0013

Palliative resection of the primary tumour is associated with increased survival in patients with synchronous metastatic colorectal cancer: a nationwide population-based study from The Netherlands
J. Lam-Boer, et al., O-0014

Modern treatment of rectal cancer closes the gap between common adenocarcinoma and mucinous carcinoma
N. Hugen, et al., O-0015

RAINBOW: Global, phase 3, randomized, double-blind study of ramucirumab plus paclitaxel vs placebo plus paclitaxel patients with previously treated gastric or gastroesophageal junction adenocarcinoma – patient-reported outcomes and performance status
S. Al-Batran, et al., O-0016

Phase III study of apatinib in advanced gastric cancer: A randomized, double-blind, placebo-controlled trial
J. Li, et al. O-0029

9:00

Discussant
Thomas Seufferlein, MD

9:15

Session adjourns

Session XI: ESMO session: Focus on young medical oncologist

Parallel with Session VIII: Meet the expert concurrent presentations, Session IX – Presentation of selected abstracts IIA and Session X – Presentation of selected abstracts IIB

Chairs: Roberto Labianca, MD and Erika Martinelli, MD, PhD

8:00

Why invest in Young Medical Oncologist?
Fortunato Ciardiello, MD, PhD

8:15

The roles for circulating biomarkers in gastrointestinal cancer
Leticia De Mattos-Arruda, MD

8:30

Are we ready to select patients in mCRC cancer?
Sebastian Stintzing, MD

8:45

BRAF mutant colorectal cancer: A different entity
Loredana Vecchione, MD, PhD

9:00

ESMO Young Oncologist Committee Presentation
Erika Martinelli, MD, PhD

Session XII: Clinical trials for GI oncologists Trials and endpoints in GI cancer

Chairs: Aimery de Gramont, MD and Alberto Sobrero, MD

9:15

Have we made progress in the role of PET in response prediction?
Wim Oyen, MD

9:30

Can the pathologist predict the response of chemotherapy in GI malignancies?
Laura Rubbia-Brandt, MD, PhD

9:45

What is the right signal to go to phase III
Johanna C. Bendell, MD

10:00

Magnitude of benefit (delta and HRs)
Alberto Sobrero, MD

10:15

Discussion

10:30

Break and poster viewing
Abstracts to be presented: Clinical/basic CRC abstracts

Session XIII: Multimodality therapy for rectal cancer

Chairs: David Cunningham, MD and Karin Haustermans, MD, PhD

11:00

Keynote lecture 3: Imaging in rectal cancer and its value for the assessment of response
Regina G.H. Beets-Tan, MD, PhD

11:30

Organ-sparing surgery in rectal cancer
Andre D’Hoore, MD, PhD

11:50

Presentation of selected abstracts
Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer: disease free survival results at interim analysis
H. J. Schmoll, et al., O-0017

5-FU with or without Oxaliplatin in locally-advanced rectal cancer – Phase III CAO/ARO/AIO-04 Study
U. Graeven, et al., O-0028

12:10

Discussant: Which neoadjuvant chemoradiotherapy regimen in rectal cancer?
Robert Glynn-Jones, FRCR, FRCP

12:30

How to intensify preoperative therapy in rectal cancer?
Pro RT
Karin Haustermans, MD, PhD
Pro chemo
David Cunningham, MD

13:00

Session adjourns

13:15

Concurrent luncheon symposia begin

14:45

Concurrent luncheon symposia adjourn

Session XIV: Highlights in cancer

Chairs: Josep Tabernero, MD, PhD and Eric Van Cutsem, MD, PhD

15:00

Keynote lecture 4:The right drug for the right patient: Phenotype or genotype?
Han van Krieken, MD

15:30

Keynote lecture 5: Can we still afford all treatment options: A health economic view
Lieven Annemans, PhD, MSc, MMan

16:00

Keynote lecture 6: Immunologic treatments for gastrointestinal cancers: Current status and future strategies
Benoît  Van den Eynde, MD, PhD

16:30

Break and poster viewing
Abstracts to be presented: Clinical/basic CRC abstracts

Session XV: Liver and peritoneal metastases

Chairs: René Adam, PhD and Thomas Gruenberger, MD

17:00

Categorization of liver limited mCRC and its approaches (neoadjuvant, conversion, palliative)
Thomas Gruenberger, MD

17:20

Is there a role for palliative resection for the primary tumor in case of metastases?
Bernard Nordlinger, MD

17:40

Multidisciplinary management of peritoneal carcinomatosis from colorectal cancer: New perspectives
Dominique Elias, MD, PhD

18:00

Liver directed therapy – When and how? (Stereotactic radiotherapy, selective intrahepatic radiospheres, drug eluting beads or intrahepatic chemotherapy)
Hapreet S. Wasan, MD, MBBS, MRCP

Session XVI: Poster discussion

Chairs: René Adam, PhD and Thomas Gruenberger, MD

18:20

Poster discussion session 1 – EGFR-targeted agents (PD-0001 – PD-0007)
Philippe Rougier, MD, PhD

18:30

Poster discussion session II – Tumor burden and biomarkers (PD-0008 – PD-0011)
Roberto Labianca, MD

18:40

Poster discussion session III – Endoscopy (PD-0012 – PD-0017)
Nadir Arber, MD, MHA

18:50

Poster discussion session IV – Miscellaneous (PD-0018 – PD-0023)
Eduardo Diaz-Rubio, MD, PhD

19:00

Session adjourns

Saturday, 28 June 2014

Session XVII: Prevention and screening of colon cancer

Chairs: Nadir Arber, MD, MHA and Antoni Castells, MD

8:30

Genetic alterations in polyps or on familial colorectal cancer screening
Antoni Castells, MD

8:50

Screening for CRC in 2014
Wolff Schmiegel, MD, PhD

9:10

Chemoprevention of colon cancer
Nadir Arber, MD, MHA

9:30

Does it matter what we eat and whether we exercise?
Jeffrey Meyerhardt, MD, MPH

9:50

Break

Session XVIII: Metastatic colorectal cancer

Chairs: Fortunato Ciardello, MD, PhD and Eric Van Cutsem, MD, PhD

10:20

What is the best cytotoxic backbone for biologicals?
Alan P. Venook, MD

10:35

A phase III trial of fluoropyrimidines (FP) plus bevacizumab (Bev) vs. Bev alone, or no treatment as maintenance strategy, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): AIO KRK 0207
D. Arnold, et al, O-0027

10:45

Maintenance treatment or stop and go: What is the standard?
Michel Ducreux, MD, PhD

11:00

Independent radiological evaluation of objective response early tumor shrinkage, and depth of response in FIRE-3 (AIO KRK-0306)
V. Heinemann, et al., O-0030

CALGB/SWOG 80405: PHASE III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC)
A. Venook, et al., O-0019

11:20

Discussant: Which biological agent and for whom?
Paulo M. Hoff, MD

11:35

Presentation of selected abstracts
Outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer randomized to FOLFIRI with or without cetuximab as first-line treatment
F. Ciardiello, et al., O-0020

Outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer randomized to FOLFOX4 with or without cetuximab as first-line treatment
S. Tejpar, et al., O-0021 

11:55

Discussant: Molecular markers beyond RAS anti-EGFR targeted agents – What is new?
Josep Tabernero, MD, PhD

12:10

Presentation of selected abstracts
Results of a multicenter, randomized, double-blind, phase III study of TAS-102 vs. placebo, with best supportive care (BSC), in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies (RECOURSE)
T. Yoshino, et al., O-0022

CONCUR: A randomized, double-blind, placebo-controlled phase 3 study of regorafenib monotherapy in Asian patients with previously treated metastatic colorectal cancer (mCRC)
J. Li, et al., O-0023

12:30

Discussant
Richard M. Goldberg, MD

12:40

What to do in BRAF mutant CRC patients?
Heinz-Josef Lenz, MD

12:55

Session adjourns

13:10

Concurrent luncheon symposia begin

14:40

Concurrent luncheon symposia adjourn

Session XIX: Hot topics in colon cancer

Chairs: Mario Dicato, MD and Eduardo Diaz-Rubio, MD, PhD

14:55

Presentation of selected abstract
Colorectal cancer subtyping consortium (CRCSC) identifies consensus of molecular subtypes
R. Dienstmann, et al., O-0025

15:05

Are we making progress in the molecular taxonomy of colon cancer?
Sabine Tejpar, MD, PhD

15:20

Are gene signatures ready for use in the selection of patients for adjuvant treatment?
Ramon Salazar Soler, MD PhD

15:35

How to improve on the adjuvant treatment in stage III colon cancer?
Aimery de Gramont, MD

Session XX: Report on expert discussion

15:55

Presentation of outcome of expert discussion: Metastatic colorectal cancer
Mario Dicato, MD; Eric Van Cutsem, MD, PhD; and Josep Tabernero, MD, PhD

16:15

Adjourn